Seth Lederman
Net Worth

Last updated:

What is Seth Lederman net worth?

The estimated net worth of Dr. Seth Lederman is at least $13,702,524 as of 29 Jun 2022. He owns shares worth $862,524 as insider and has received compensation worth at least $12,840,000 in Tonix Pharmaceuticals Holding Corp..

What is the salary of Seth Lederman?

Dr. Seth Lederman salary is $1,070,000 per year as Co-Founder, Pres, Chief Executive Officer & Chairman in Tonix Pharmaceuticals Holding Corp..

How old is Seth Lederman?

Dr. Seth Lederman is 67 years old, born in 1958.

What stocks does Seth Lederman currently own?

As insider, Dr. Seth Lederman owns shares in one company:

Company Title Shares Price per share Total value
Tonix Pharmaceuticals Holding Corp. (TNXP) Co-Founder, Pres, Chief Executive Officer & Chairman 24,235 $35.59 $862,524

What does Tonix Pharmaceuticals Holding Corp. do?

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

TNXP logo
TNXP
Tonix Pharmaceuticals Holding Corp.
$35.59

Seth Lederman insider trading

Tonix Pharmaceuticals Holding Corp.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock, $0.001 par value 20,000 $1.71 $34,200
Purchase
Common Stock, $0.001 par value 100,000 $0.25 $24,500
Purchase
Common Stock, $0.001 par value 12,000 $0.61 $7,320
Purchase
Common Stock, $0.001 par value 16,733 $1.32 $22,088
Purchase
Common Stock, $0.001 par value 35,000 $0.68 $23,800
Purchase
Common Stock, $0.001 par value 60,000 $0.91 $54,600
Purchase
Common Stock, $0.001 par value 20,000 $1.16 $23,180
Purchase
Common Stock, $0.001 par value 5,000 $2.49 $12,440
Purchase
Common Stock, $0.001 par value 25,000 $2.38 $59,375
Purchase
Common Stock, $0.001 par value 500 $4.64 $2,320
Purchase
Common Stock, $0.001 par value 500 $4.58 $2,290
Purchase
Common Stock, $0.001 par value 500 $4.55 $2,275
Purchase
Common Stock, $0.001 par value 3,000 N/A N/A
Purchase
Common Stock, $0.001 par value 4,000 N/A N/A
Purchase
Common Stock, $0.001 par value 5,300 N/A N/A
Purchase
Common Stock, $0.001 par value 15,000 N/A N/A
Purchase
Common Stock, $0.001 par value 5,000 N/A N/A
Purchase
Common Stock, $0.001 par value 5,000 N/A N/A
Purchase
Common Stock, $0.001 par value 5,000 N/A N/A
Purchase
Common Stock, $0.001 par value 20,000 N/A N/A
Purchase
Common Stock, $0.001 par value 98,000 N/A N/A
Purchase
Common Stock Purchase Warrant 10,000 N/A N/A
Purchase
Common Stock, $0.001 par value 10,000 N/A N/A
Purchase
Common Stock, $0.001 par value 20,000 N/A N/A
Purchase
Common Stock, $0.001 par value 25,000 N/A N/A
Purchase
Common Stock, $0.001 par value 8,000 N/A N/A
Purchase
Common Stock, $0.001 par value 6,000 N/A N/A
Purchase
Common Stock, $0.001 par value 6,000 N/A N/A
Purchase
Common Stock, $0.001 par value 1,000 N/A N/A
Purchase
Common Stock, $0.001 par value 1,000 N/A N/A
Purchase
Common Stock, $0.001 par value 1,000 N/A N/A
Purchase
Common Stock, $0.001 par value 1,000 N/A N/A
Purchase
Common Stock, $0.001 par value 1,000 N/A N/A
Purchase
Common Stock, $0.001 par value 1,000 N/A N/A
Purchase
Common Stock, $0.001 par value 1,000 N/A N/A
Purchase
Common Stock, $0.001 par value 1,000 N/A N/A
Purchase
Common Stock, $0.001 par value 1,000 N/A N/A
Purchase
Common Stock, $0.001 par value 1,000 N/A N/A
Purchase
Common Stock, $0.001 par value 5,000 N/A N/A
Purchase
Series A common stock purchase warrant 11,765 N/A N/A
Purchase
Common Stock, $0.001 par value 11,765 N/A N/A
Purchase
Common Stock, $0.001 par value 1,000 N/A N/A

Tonix Pharmaceuticals Holding Corp. key executives

Tonix Pharmaceuticals Holding Corp. executives and other stock owners filed with the SEC: